Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C P Cross

Showing results (191-200 of 221) with videos related to

Pageof 23
Sort By:
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Blood|November 8, 2019
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia veraAmi B Patel, Anca Franzini, Emilie Leroy, et al.
Leukemia|May 31, 2020
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remissionKaterina Machova Polakova, Hana Zizkova, Jan Zuna, et al.
British Journal of Haematology|May 26, 2020
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML studyDragana Milojkovic, Nicholas C P Cross, Sahra Ali, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
American Journal of Hematology|April 13, 2020
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genesJuliana Schwaab, Nicole Naumann, Johannes Luebke, et al.
British Journal of Haematology|March 9, 2011
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaLetizia Foroni, Gill Wilson, Gareth Gerrard, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Blood|May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Pageof 23

Showing results (191-200 of 221) with videos related to

Sort By:
Pageof 23
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Blood|November 8, 2019
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia veraAmi B Patel, Anca Franzini, Emilie Leroy, et al.
Leukemia|May 31, 2020
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remissionKaterina Machova Polakova, Hana Zizkova, Jan Zuna, et al.
British Journal of Haematology|May 26, 2020
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML studyDragana Milojkovic, Nicholas C P Cross, Sahra Ali, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
American Journal of Hematology|April 13, 2020
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genesJuliana Schwaab, Nicole Naumann, Johannes Luebke, et al.
British Journal of Haematology|March 9, 2011
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaLetizia Foroni, Gill Wilson, Gareth Gerrard, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Blood|May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Pageof 23